ArticleFrontiers in pharmacology2022

Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.

Yan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.